First-time prescribing of tirzepatide increased throughout 2023, and we see evidence of the first prescribing of AOM tirzepatide (Zepbound) in December 2023
By promoting weight loss and improving metabolic health, Semaglutide reduces obesity-related health risks, including cardiovascular disease
some work in inflammatory bowel disease (PMID: 22300085) A clinical trial has been registered, though its current status is unclear (PMID: 40756949) Regulatory note: BPC-157 is prohibited by WADA/USADA for sport use (added to the Prohibited List in 2022)
Our contact number is +1 (714) 709-8000
How IV Therapy Supports Your GLP-1 Journey: Hydration, Energy & Recovery GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are changing the landscape of weight management
This can translate to improvements in acne, hair growth patterns, and scalp hair retention